- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01345448
Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy
Study of Safety and IOP Lowering Efficacy of Transdermal Brimonidine Therapy
연구 개요
상세 설명
Glaucoma is the leading cause of irreversible blindness worldwide, with primary open-angle glaucoma the most common form of glaucoma. Vision loss is caused by damage to the optic nerve. The modern goals of glaucoma management are to avoid glaucomatous damage, nerve damage, preserve visual field and total quality of life for patients with minimal side effects.
Although intraocular pressure is only one of the major risk factors for glaucoma, lowering it via various pharmaceuticals and/or surgical techniques is currently the mainstay of glaucoma treatment. Intraocular pressure can be lowered with medication, usually eye drops. There are several different classes of medications to treat glaucoma with several different medications in each class. In order to prevent blindness from glaucoma, it is critical that patients take their glaucoma eye drops accurately and faithfully for the rest of their lives. Poor compliance with medications and follow-up visits is a major reason for vision loss in glaucoma patients. In addition, coordination involved in placing an eye drop in the eye is considerably more difficult and unpleasant to patients than many other therapies. Thus, localized transdermal eyelid lotion would create a leap in safety of drug delivery while at the same time rendering ocular drugs easy and non traumatic to use.
연구 유형
등록 (예상)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
California
-
Visalia, California, 미국, 93277
- 모병
- Eye Surgical and Medical Associates
-
연락하다:
- Michael Boone, MD
- 전화번호: 559-627-9393
- 이메일: drboone@visaliaeyecare.com
-
연락하다:
- Amy Smith
- 전화번호: (559)627-9393
- 이메일: amys@visaliaeyecare.com
-
부수사관:
- Michael Boone, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients with a clinical diagnosis of stable Chronic Open Angle Glaucoma and stable Vital signs who are controlled on a stable dose of a single IOP lowering agent and who have demonstrated stable target intraocular pressure for a minimum of 3 months.
- Male or Female patients aged at least 18 years of age.
- Females of childbearing potential must use a reliable form of contraception throughout the study period such as celibacy, birth control pills, or condoms.
- A negative urine pregnancy test result at Screening and Baseline (Day 1) for women of childbearing potential
- Best-Corrected Visual Acuity of 20/800 or better in both eyes
- Written informed consent.
- Ability to follow instructions and likely to complete all study visits based upon patient factors such as cognition, reliability, motivation, and ability to obtain reliable transportation to study site.
Exclusion Criteria:
- Uncontrolled glaucoma
- Glaucoma requiring more than a single agent for IOP control
- Patients with a corneal thickness greater then 620 micrometers
- Female patients who are pregnant, nursing, or planning a pregnancy during the study
- Patient who has any situation or condition, which in the investigator's opinion, may put the patient at a significant risk, may confound the study result or may interfere significantly with the participation in the study
- Uncontrolled or labile hypertension
- At the conclusion of the washout period any study participant with an IOP lower than 22 or greater than 35 mmHg.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Intraocular Pressure
기간: Day one, every hour for twelve hours.
|
Day one, every hour for twelve hours.
|
Heart Rate
기간: Day one, every hour for twelve hours.
|
Day one, every hour for twelve hours.
|
Blood Pressure
기간: Day one, every hour for twelve hours.
|
Day one, every hour for twelve hours.
|
Intraocular Pressure
기간: Day two twice, once in the AM, once in the PM.
|
Day two twice, once in the AM, once in the PM.
|
Intraocular Pressure
기간: Day seven, once.
|
Day seven, once.
|
Intraocular Pressure
기간: Day fourteen, once.
|
Day fourteen, once.
|
Intraocular Pressure
기간: Day twenty one, once.
|
Day twenty one, once.
|
Intraocular Pressure
기간: Day twenty eight, once.
|
Day twenty eight, once.
|
Heart Rate
기간: Day two twice, once in the AM, once in the PM.
|
Day two twice, once in the AM, once in the PM.
|
Heart Rate
기간: Day seven, once.
|
Day seven, once.
|
Heart Rate
기간: Day fourteen, once.
|
Day fourteen, once.
|
Heart Rate
기간: Day twenty one, once.
|
Day twenty one, once.
|
Heart Rate
기간: Day twenty eight, once.
|
Day twenty eight, once.
|
Blood Pressure
기간: Day two twice, once in the AM, once in the PM.
|
Day two twice, once in the AM, once in the PM.
|
Blood Pressure
기간: Day seven, once.
|
Day seven, once.
|
Blood Pressure
기간: Day fourteen, once.
|
Day fourteen, once.
|
Blood Pressure
기간: Day twenty one, once.
|
Day twenty one, once.
|
Blood Pressure
기간: Day twenty eight, once.
|
Day twenty eight, once.
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Padma Nanduri, MD
- 연구 책임자: Michael Boone, MD
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- White Rabbit 2010-0001
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Brimonidine에 대한 임상 시험
-
Genovate Biotechnology Co., Ltd.,Allergan Medical알려지지 않은
-
Cornerstone Health Care, PAAllergan완전한
-
Alcon Research완전한